![Woman with text "repeating stories, memory issues, losing things" and It's hard to see from the outside. AMYVID can help](/assets/images/hcp/hero-charlotte-desktop-v2.jpg)
IT'S HARD TO SEE FROM THE OUTSIDE. AMYVID CAN HELP.1
Amyvid is used to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. Amyvid is an adjunct to other diagnostic evaluations.4
In 2023, the Centers for Medicare & Medicaid Services (CMS) removed the national coverage determination (NCD) for beta amyloid PET (§220.6.20). This ends the requirement of coverage with evidence development (CED) for beta amyloid PET imaging. Removal of the NCD from §220.6.20 permits Medicare coverage determinations to be made by Medicare Administrative Contractors (MACs).5
With new therapies focusing on earlier stages in the disease continuum, confirming the presence of Alzheimer’s disease (AD) pathology to aid in determining an AD diagnosis as early as possible is essential.6,7
Learn more about accuracy with Amyvid.
Learn more about Amyvid's procedure time and image center scheduling.
PET=positron emission tomography.
Learn which patients may be right for Amyvid
References:
- Clark CM, Schneider JA, Bedell BJ, et al; for AV45-A07 Study Group. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011;305(3):275-283.
- Gauthier S, Rosa-Neto P, Morais JA, et al. World Alzheimer Report 2021: Journey Through the Diagnosis of Dementia. London, England: Alzheimer’s Disease International; 2021. Accessed January 25, 2023. https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf
- DiBenedetti DB, Slota C, Wronski SL, et al. Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020;12(1):90. doi: 10.1186/s13195-020-00659-6
- Amyvid (florbetapir F 18 injection). Prescribing Information. Lilly USA, LLC.
- CMS.gov. Beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431R). Accessed October 13, 2023. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=308
- Porsteinsson AP, Isaacson RS, Knox S, et al. Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386.
- Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017;9(1):60. doi:10.1186/s13195-017-0283-5